质子治疗对比调强放疗治疗头颈部肿瘤的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入11项研究共3087例头颈部肿瘤患者(质子治疗606例,调强放疗2481例),比较两种放疗的疗效与安全性。质子治疗在多个急性2级毒性反应上优于调强放疗,并在1年、2年、5年总生存及2年、5年无病生存方面显示改善。
要点
- 质子治疗与调强放疗相比,急性1级恶心发生率降低(OR=0.34,95%CI 0.13-0.84,p=0.02)。
- 2级毒性中,质子治疗在口腔黏膜炎、味觉障碍、吞咽困难、乏力、疼痛和体重下降方面均优于调强放疗。
- 质子治疗在1年、2年、5年总生存及2年、5年无病生存方面均优于调强放疗。
核心结论
- 质子治疗较调强放疗显示出更优的总生存、无病生存和局部控制率,且安全性更好,尤其在2级急性毒性事件方面。
研究设计与样本
- 系统评价与Meta分析,检索Pubmed、ScienceDirect、Embase、Scopus和Web of Science数据库,最终纳入11项研究,共3087例患者(质子治疗606例,调强放疗2481例)。
- 采用随机效应模型Meta分析,估计疗效与安全性结局的 hazard ratio(HR)和 odds ratio(OR)。
主要发现
- 急性1级恶心:质子治疗对比调强放疗 OR=0.34(95%CI 0.13-0.84,p=0.02)。
- 2级毒性:口腔黏膜炎 OR=0.44(p<0.0001)、味觉障碍 OR=0.35(p=0.02)、吞咽困难 OR=0.36(p<0.0001)、乏力 OR=0.29(p=0.001)、疼痛 OR=0.34(p=0.01)、体重下降 OR=0.54(p=0.02),均为质子治疗对比调强放疗。
- 3级吞咽困难:质子治疗对比调强放疗 OR=0.44(p<0.0001)。
- 总生存:1年 HR=0.43(p=0.02)、2年 HR=0.44(p<0.0001)、5年 HR=0.78(p=0.004),均为质子治疗对比调强放疗。
- 无病生存:2年 HR=0.65(p=0.03)、5年 HR=0.81(p=0.03),均为质子治疗对比调强放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To comprehensively evaluate the therapeutic efficacy and safety when utilizing proton therapy (PT) versus intensity-modulated radiation therapy (IMRT) in head and neck cancer patients. Pubmed, ScienceDirect, Embase, Scopus, and Web of Science were systematically searched for studies on comparative PT and IMRT outcomes. We performed a random effect model meta-analysis to estimate the hazard ratio (HR) and odds ratio (OR) for efficacy and safety outcome variables between PT and IMRT. From 641 identified articles, 11 studies met the inclusion criteria, comprising 3087 patients (606 treated with PT and 2481 with IMRT). On toxicity analysis, PT is associated with decreased acute grade 1 nausea (OR = 0.34, 95% CI: 0.13-0.84, p = 0.02) compared to IMRT. In grade 2 toxicity, PT showed significant advantages over IMRT in mucositis (OR = 0.44, p < 0.0001), dysgeusia (OR = 0.35, p = 0.02), dysphagia (OR = 0.36, p < 0.0001), fatigue (OR = 0.29, p = 0.001), pain (OR = 0.34, p = 0.01), and weight loss (OR = 0.54, p = 0.02). Proton therapy also exhibited increased safety in grade 3 dysphagia incidence (OR = 0.44, p < 0.0001) compared to IMRT. PT demonstrated improved overall survival (OS) compared to IMRT across multiple time points: 1-year OS (HR = 0.43, p = 0.02), 2-year OS (HR = 0.44, p < 0.0001), and 5-year OS (HR = 0.78, p = 0.004). In terms of disease-free survival (DFS), PT also showed improved outcomes at 2-year DFS (HR = 0.65, p = 0.03) and 5-year DFS (HR = 0.81, p = 0.03). Proton therapy demonstrated superior overall survival (OS), disease-free survival (DFS), and better local control rate (LCR) compared to IMRT. The data also showed better safety outcomes in PT patients, particularly when involving grade 2 acute toxicity events.
引用
- Vasudevan SS, Deeb H, Katta A, et al. Efficacy and safety of proton therapy versus intensity-modulated radiation therapy in the treatment of head and neck tumors: A systematic review and meta-analysis. Head Neck. 2024. PMID: 39007360. doi:10.1002/hed.27877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。